Philip Morris International Enters the ‘Year of Unsmoke’—Calls on All Those Who Can Empower a Smoke-Free Future
Philip Morris International Inc. (PMI) (NYSE:PM) today launched “The Year of Unsmoke,” an urgent call to action to smokers, nonsmokers, regulators and agents of change across the world to drive a better future for the world’s 1.1 billion smokers and their families, loved ones and communities.
The call to action stems from the knowledge that despite global efforts to encourage people to quit or not to start smoking, the World Health Organization predicts that there will still be approximately the same number of people who smoke in 2025 as do today.
Jacek Olczak, PMI’s chief operating officer, announced the company’s ambition to lead the way toward truly global change: “It should be crystal clear: If you don’t smoke, don’t start. If you smoke, quit. If you don’t quit, change. That’s unsmoking. It is a fact that burning generates the vast majority of harmful chemicals found in cigarette smoke. Eliminating the combustion dramatically reduces the levels of harmful chemicals. There is a growing consensus among scientists and public health experts that products that do not burn and are backed by science are a much better choice than cigarettes.”
PMI’s mission is to create a smoke-free future backed by science, technology and innovation to offer less harmful choices to those who would otherwise continue smoking.
Mr. Olczak added: “Many people and organizations still prefer to focus on an ideological fight. The controversy they generate continues to confuse people who smoke, and those skeptics are quickly becoming the biggest advocates of continued cigarette smoking. The consequences of this confusion are that people continue to smoke cigarettes, whose harmful effects are well known. It is common sense to move away from ideology and take concrete steps forward together toward a common goal: remove smoke from our world and encourage 1.1 billion men and women to switch to better alternatives if they do not quit.”
The company launched the initiative as a rallying cry to drive global progress, as well as to end a political stalemate in policymaking about better alternatives to cigarette smoking.
The “Year of Unsmoke” will help to drive this goal, through conversation around the importance of going smoke-free, extending to smokers, nonsmokers, engaged citizens, policymakers, regulators and key stakeholders. “To enable people to make an informed choice about the better alternatives that are available to them is the right thing to do, and policymakers have a crucial role in making that happen. We are asking for a unified global conversation to drive real change.”
A new study, commissioned by PMI and carried out by respected global research company Povaddo, said eight out of 10 (79 percent) people globally, support PMI working with governments, regulators and public health experts to phase-out cigarettes in favor of smoke-free alternatives, and 73 percent believe it is a good thing for PMI to transform its business model away from cigarettes and to only sell alternatives like e-cigarettes and heat-not-burn tobacco products.
The “Year of Unsmoke” kicks off a campaign called “Unsmoke Your World.” The core message for the campaign, which PMI hopes to seed across the world, is:
If you don’t smoke, don’t start
If you smoke, quit
If you don’t quit, change
To unsmoke is to rid smoke from your life. It unites smokers and nonsmokers who want to unsmoke themselves, family and friends. The best way to unsmoke is to quit cigarettes and nicotine altogether; the next best way is to change to better alternatives.
To date, PMI has invested over USD$6 billion in the research, development, manufacturing and commercialization of smoke-free products and dedicated 400+ scientists and engineers to research and development.
Philip Morris International: Building a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. For more information, see our PMI and PMIScience websites.
About Unsmoke Your World
PMI is transforming its business and increasing awareness of the urgent need to become smoke-free as well as awareness of better alternatives for smokers who would otherwise continue to smoke. PMI is producing smoke-free products that are a better choice for smokers than continued cigarette smoking and can benefit public health.
Unsmoke is a PMI initiative to speed up an historic change in public health. Through the Unsmoke movement we want to bring together a community of people who can accelerate this change by becoming advocates of the message that for smokers who would otherwise continue to smoke, there are better alternatives to choose from.
Unsmoke Your World is a global conversation that inspires human stories—for the people, by the people.
About the Povaddo Survey
This survey was carried out March 26-28,2019, by Povaddo, an international opinion research firm, on behalf of Philip Morris International. The survey fielded a total of 4,545 online interviews among legal age, general population adults across 20 countries (Argentina, Australia, Brazil, Colombia, Germany, Hong Kong, Israel, Italy, Japan, Malaysia, Mexico, New Zealand, Poland, Singapore, South Korea, Spain, Switzerland, Taiwan, the United Kingdom, and the United States). The survey carries a margin of error of +/- 1.5% at the 95 percent confidence interval.
Philip Morris International media office
T: +41 (0)58 242 4500
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetMedia Group takes over the management of financial platform Investing.com's European advertising space23.7.2019 08:07:00 CEST | Press release
NetMedia Group, media B2B leader in Europe in the world of business information, and Investing.com, second largest financial services and information platform in Europe, are to form a partnership, with NetMedia Group handling the sales of advertising space for Investing.com. With average traffic of over 21 million unique users totaling over 175 million sessions in 31 countries, Investing.com is one of the top three global financial websites and has the most downloaded financial management app. For Investing.com, the aim of the new partnership is to maximize digital advertising revenue through the NetMedia Group's European teams. NetMedia Group's goal is to expand its advertising services by offering a new vertical market for finance, in order to boost the range of services it has available to decision-makers for upper socio-professional target groups. About NetMedia Group: NetMedia Group is a B2B media group located in five countries across Europe; it employs nearly 150 staff members a
Frost & Sullivan Names Luminati the 2019 Global Market Leader in the Enterprise IP Proxy Networks Market23.7.2019 08:00:00 CEST | Press release
Luminati, the Israeli company that allows businesses to experience the web through the eyes of individual consumers throughout the world, today announced it has received a Market Leadership Award in the first independent analysis of the sector. Luminati’s enterprise IP proxy network (IPPN) services for global retailers, brand owners and advertising networks feature strongly in the report by analyst firm Frost & Sullivan. The report outlines a relatively new, but rapidly growing market and recognizes Luminati’s leading position in the provision of solutions that are increasingly important for businesses to remain competitive and compliant in the digital landscape. [S1] “The market for enterprise IP proxy network solutions is in its early growth stages, basically being invented by Luminati only a few years ago. With the more specialized targeting of customers by demographics and location, companies are finding it more difficult than ever to do competitive analysis and verify advertising,
LifeSpan BioSciences Releases Best-In-Class PathPlus™ Top Performing Immunohistochemistry Antibodies for Cancer Targets23.7.2019 08:00:00 CEST | Press release
LifeSpan BioSciences, Inc. (LSBio™), the industry leader in molecular pathology, today announced the first release of its PathPlus™ series of antibodies. These 565 antibodies were selected from among thousands tested and identified to be the best performing reagents for immunohistochemical detection of 200 high-value cancer targets in formalin-fixed paraffin-embedded human tissues. Antibody validation has become an industry roadblock as thousands of antibodies have become available to customers who face difficult choices in determining which antibodies are the best performers for each application, including immunohistochemistry, flow cytometry, ELISA, Western blot, or immunofluorescence. Antibodies that perform well in one assay, such as IHC, may not be the most specific reagent for another assay, such as flow cytometry. “Identifying the optimal reagents to use in their experiments is a pain point for researchers,” said LSBio CEO Heather Holemon. “There is a tremendous need to identify
IDEMIA Will Present Its H1 2019 Financial Results to Investors on July 30, 201923.7.2019 07:00:00 CEST | Press release
IDEMIA, the world leader in Augmented Identity, today announced that it will present its H1 2019 financial results to investors on Tuesday July 30, 2019. Yann Delabrière (CEO) and Laurent Lemaire (CFO) will be presenting the financial results and taking questions the same day at 3:30 pm CET (2:30 pm London Time / 9:30 am New York Time). For more information, please refer to our website: https://investors.idemia.com/ About IDEMIA IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whet
Gain Therapeutics SA Announces Award Notification of a €1.4M Grant Support From Eurostars-2 Together With the Institute for Research in Biomedicine and Neuro-Sys SAS After Having Scored 2nd Among 325 Eligible Applications23.7.2019 06:30:00 CEST | Press release
Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in central nervous system (CNS) diseases, today announced that together with Dr. Maurizio Molinari from the Institute for Research in Biomedicine, Bellinzona (Switzerland) affiliated to the Università della Svizzera italiana (USI) and Neuro-Sys SAS in Gardanne (France), it has received funding support from Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency. This grant will further strengthen Gain Therapeutics’s novel therapeutic approach for targeting rare diseases in the CNS, where lysosomal misfolded enzymes lead to sever clinical phenotypes, where no treatment is available and/or high unmet medical needs still do afflict patients, families and carers. This funding will support the development of the drugs portfolio of Gain Therapeutics for the
iBASIS Accelerates Growth With JC Geha as Chief Operating Officer23.7.2019 06:00:00 CEST | Press release
iBASIS, provider of communications solutions for operators and digital players worldwide, today announced the appointment of JC Geha as its COO. He will take his new post effective August 1, and be based at iBASIS’ headquarters in Lexington, Massachusetts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005757/en/ JC Geha (Photo: Business Wire) Formerly Senior Vice President, Head of International Technology and Services for Deutsche Telekom, and of Managed Services for Ericsson, Geha brings to iBASIS an impressive track record of profitable growth, technology and digital transformation expertise. His expertise spans 25 years of deep global industry relationships across the United States, Europe, Middle East, and Africa. Geha will lead iBASIS’ global operations, engineering, IT, and product development. He will report to iBASIS’ CEO and founder of the Group Tofane Global, Alexandre Pébereau, with the responsibility of g